Trial Profile
A 2-part, multi-center, open-label trial to study safety, tolerability and pharmacodynamic (PD) effects of siponimod in healthy cytochrome P450(CYP)2C9 poor metabolizers (PM) compared to extensive metabolizers (EM) at single and multiple doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Siponimod (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Pharmacodynamics
- 06 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology